Gilead's Kite has announced positive overall survival results from a study of its CAR-T cell therapy YESCARTA (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. …
Earlier treatment with Gilead's CAR-T therapy delivers on 'overall survival'
June 19, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Budget reveals wholesaling arrangements are a future focus
March 25, 2025 - - Latest News -
Former Speaker of the House appointed as official Patron of Rare Cancers Australia
March 25, 2025 - - Latest News -
Another day, and another addition to what is now a motherload of bad ideas
March 25, 2025 - - Latest News -
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 - - Latest News -
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
What happens to the conspiracy when the industry and ministerial criticisms sound remarkably similar?
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News